These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32162191)

  • 1. HER2-positivity in mucinous cancer might be related to accompanying infiltrating ductal carcinoma histology.
    Altundag K
    Breast Cancer Res Treat; 2020 Apr; 180(3):829. PubMed ID: 32162191
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pathology of mammary mucinous carcinoma and its molecular markers].
    Zhang W; Niu Y; Zhang TX; Liu S; Liu F
    Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):777-9. PubMed ID: 24447562
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression of androgen receptors in primary breast cancer.
    Park S; Koo J; Park HS; Kim JH; Choi SY; Lee JH; Park BW; Lee KS
    Ann Oncol; 2010 Mar; 21(3):488-492. PubMed ID: 19887463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new model for ductal carcinoma in situ suggests strategies for treatment.
    Gullick WJ
    Breast Cancer Res; 2002; 4(5):176-8. PubMed ID: 12223119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of HER2 protein examination in ductal carcinoma in situ.
    Horimoto Y; Tokuda E; Arakawa A; Kosaka T; Saito M; Kasumi F
    J Surg Res; 2011 May; 167(2):e205-10. PubMed ID: 20018297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry.
    Wu C; Guo X; Wang W; Wang Y; Shan Y; Zhang B; Song W; Ma S; Ge J; Deng H; Zhu M
    BMC Cancer; 2010 Apr; 10():123. PubMed ID: 20356418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
    Ubago JM; Blanco LZ; Shen T; Siziopikou KP
    Am J Clin Pathol; 2019 Jul; 152(2):169-176. PubMed ID: 30984969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sweat gland carcinoma with mucinous and infiltrating duct-like patterns.
    Yamamoto O; Nakayama K; Asahi M
    J Cutan Pathol; 1992 Aug; 19(4):334-9. PubMed ID: 1331212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status.
    Layfield LJ; Lewis C
    Anal Quant Cytol Histol; 2007 Aug; 29(4):239-43. PubMed ID: 17879632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
    Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
    Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression.
    Chang WC; Hsu HH; Yu JC; Ko KH; Peng YJ; Tung HJ; Chang TH; Hsu GC
    Eur J Radiol; 2014 Jun; 83(6):935-941. PubMed ID: 24666513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
    Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
    Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microcysts and breast cancer: a study of biological markers in archival biopsy material.
    Tran DD; Lawson JS
    Breast Cancer Res Treat; 2002 Oct; 75(3):213-20. PubMed ID: 12353810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67 is a prognostic marker for hormone receptor positive tumors.
    Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
    Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Histochemical study of estradiol receptors and morphologic parameters in breast cancer].
    Berger G; Frappart L; Feroldi J
    Bull Assoc Anat (Nancy); 1982 Dec; 66(195):431-9. PubMed ID: 6305447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASO Author Reflections: Selecting Patients for Elimination of Surgery Trials-Predicting Residual Invasive and In Situ Disease in Patients with HER2-Positive Breast Cancer After Neoadjuvant Systemic Therapy.
    Sun SX; Kuerer HM
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):804-805. PubMed ID: 31654165
    [No Abstract]   [Full Text] [Related]  

  • 19. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.
    Vogl G; Dietze O; Hauser-Kronberger C
    Histopathology; 2005 Dec; 47(6):617-24. PubMed ID: 16324200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.
    Nye L; Rademaker A; Gradishar WJ
    Clin Breast Cancer; 2017 Jul; 17(4):e185-e189. PubMed ID: 28185739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.